These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 25906293)
1. Hypoxia-Sensitive Metal β-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis. Lord RM; Hebden AJ; Pask CM; Henderson IR; Allison SJ; Shepherd SL; Phillips RM; McGowan PC J Med Chem; 2015 Jun; 58(12):4940-53. PubMed ID: 25906293 [TBL] [Abstract][Full Text] [Related]
2. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features. Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963 [TBL] [Abstract][Full Text] [Related]
3. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents. Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192 [TBL] [Abstract][Full Text] [Related]
4. On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes. Yellol GS; Donaire A; Yellol JG; Vasylyeva V; Janiak C; Ruiz J Chem Commun (Camb); 2013 Dec; 49(98):11533-5. PubMed ID: 24177492 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxic hydrogen bridged ruthenium quinaldamide complexes showing induced cancer cell death by apoptosis. Lord RM; Allison SJ; Rafferty K; Ghandhi L; Pask CM; McGowan PC Dalton Trans; 2016 Aug; 45(33):13196-203. PubMed ID: 27417660 [TBL] [Abstract][Full Text] [Related]
6. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes. Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807 [TBL] [Abstract][Full Text] [Related]
7. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents. Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046 [TBL] [Abstract][Full Text] [Related]
9. Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells. Zeng L; Chen Y; Huang H; Wang J; Zhao D; Ji L; Chao H Chemistry; 2015 Oct; 21(43):15308-19. PubMed ID: 26338207 [TBL] [Abstract][Full Text] [Related]
10. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents. Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276 [TBL] [Abstract][Full Text] [Related]
11. Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands. Ludwig G; Ranđelović I; Maksimović-Ivanić D; Mijatović S; Bulatović MZ; Miljković D; Korb M; Lang H; Steinborn D; Kaluđerović GN ChemMedChem; 2014 Jul; 9(7):1586-93. PubMed ID: 24470190 [TBL] [Abstract][Full Text] [Related]
12. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901 [TBL] [Abstract][Full Text] [Related]
13. β-Ketoiminato Iridium(III) Organometallic Complexes: Selective Cytotoxicity towards Colorectal Cancer Cells HCT116 p53-/. Lord RM; Zegke M; Henderson IR; Pask CM; Shepherd HJ; McGowan PC Chemistry; 2019 Jan; 25(2):495-500. PubMed ID: 30362193 [TBL] [Abstract][Full Text] [Related]
14. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents. Ma W; Guo L; Tian Z; Zhang S; He X; Li J; Yang Y; Liu Z Dalton Trans; 2019 Apr; 48(15):4788-4793. PubMed ID: 30892340 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, Characterization, and Biological Properties of Steroidal Ruthenium(II) and Iridium(III) Complexes Based on the Androst-16-en-3-ol Framework. Koch V; Meschkov A; Feuerstein W; Pfeifer J; Fuhr O; Nieger M; Schepers U; Bräse S Inorg Chem; 2019 Dec; 58(23):15917-15926. PubMed ID: 31714764 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246 [TBL] [Abstract][Full Text] [Related]
18. Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor. Yang Y; Gao Y; Sun Y; Zhao J; Gou S J Med Chem; 2023 Oct; 66(19):13731-13745. PubMed ID: 37788351 [TBL] [Abstract][Full Text] [Related]
19. Heteroleptic mononuclear compounds of ruthenium(ii): synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos. Lenis-Rojas OA; Fernandes AR; Roma-Rodrigues C; Baptista PV; Marques F; Pérez-Fernández D; Guerra-Varela J; Sánchez L; Vázquez-García D; Torres ML; Fernández A; Fernández JJ Dalton Trans; 2016 Dec; 45(47):19127-19140. PubMed ID: 27868117 [TBL] [Abstract][Full Text] [Related]
20. Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy. Zheng K; Wu Q; Wang C; Tan W; Mei W Anticancer Agents Med Chem; 2017; 17(1):29-39. PubMed ID: 27349451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]